Remove Generic Medicine Remove Packaging Remove Pharmaceutical Companies
article thumbnail

Parallel import of medicinal products: regulatory update

European Pharmaceutical Review

This is due to the regulatory requirements imposed on parallel imported medicinal products in various Member States, the fulfilment of which often requires repackaging. Repackaging a medicinal product… means that the trademark is reapplied by an entity other than the trademark proprietor.”

article thumbnail

Halting Europe’s essential medicines manufacturing exodus

European Pharmaceutical Review

This left pharmaceutical companies in Europe with no European API supply source, and only a few suppliers in Asia. The recent update to the EC Urban Waste Directive, part of the environment package ‘Towards Zero Pollution,’ 4 has a disproportionate producer responsibility principle that will incur considerable extra costs.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Why are clinical trials struggling with diversity?

pharmaphorum

Within pharma and healthcare, where greater representation has been proven to lead to better health outcomes for all patients and the pharmaceutical companies developing medicines, change is also happening. As a Non-Clinical Assessor at MHRA he assessed non-clinical data packages for new and generic medicines.

Packaging 143
article thumbnail

Navigating tariffs and diplomacy: the future of India-US pharmaceutical trade

Pharmaceutical Technology

More specifically, the Indian Pharmaceutical Alliance, an organisation representing the country’s largest pharmaceutical companies, has urged the government to reduce import tariffs from the current 10% to zero for pharmaceutical imports from the US. Give your business an edge with our leading industry insights.